GENELUX Corp cotiza a 2.55 USD y tiene una capitalización bursátil de $115M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia v…
| Periodo | 2026-05 | 2026-03 | 2025-11 | 2025-08 |
|---|---|---|---|---|
| Real | $-0.20 | $-0.24 | $-0.21 | $-0.20 |
| Estimado | $-0.20 | $-0.22 | $-0.21 | $-0.22 |
| Sorpresa | +0.0% | -9.1% | +0.0% | +9.1% |
| Métrica | GNLX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -415175.0% | -38.6% | -415136.4% |
| Net Margin | -401812.5% | -33.6% | -401778.9% |
| FCF Margin | -329575.0% | -13.9% | -329561.1% |
| ROE | -278.5% | -40.4% | -238.1% |
| ROA | -168.9% | -32.0% | -136.9% |
| Current Ratio | 2.43 | 2.84 | -0.41 |
| Debt / Equity | — | 0.28 | — |